ストックスクリーナーアプリを入手
0.6367
1.59%
-0.0103
アフターアワーズ：
.65
0.0133
+2.09%
前日終値:
$0.647
開ける：
$0.65
24時間の取引高:
287.45K
Relative Volume:
0.39
時価総額：
$25.23M
収益：
$1.04M
当期純損益:
$-67.50M
株価収益率:
-0.3312
EPS:
-1.9222
ネットキャッシュフロー:
$-60.67M
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
+7.21%
6か月 パフォーマンス:
-85.98%
1年 パフォーマンス:
-73.58%
1日の値動き範囲:
$0.6352
$0.6515
1週間の範囲:
$0.6069
$0.6759
52週間の値動き範囲:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
名前
Vistagen Therapeutics Inc
セクター
電話
650-577-3600
住所
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6367 | 25.63M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2025-12-17 | ダウングレード | Stifel | Buy → Hold |
| 2025-12-17 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-07 | アップグレード | Maxim Group | Hold → Buy |
| 2022-07-22 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 開始されました | Robert W. Baird | Outperform |
| 2021-02-18 | 開始されました | Jefferies | Buy |
| 2021-01-04 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2018-02-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-28 | 開始されました | Maxim Group | Buy |
すべてを表示
Vistagen Therapeutics Inc (VTGN) 最新ニュース
Vistagen Therapeutics (VTGN) Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesExpert Market Insights - Newser
VTGN Stock Price, Quote & Chart | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
VistaGen Appoints New Chief Medical Officer to Advance Pipeline - The Globe and Mail
VTGN: Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027 - TradingView
[Form 4] Vistagen Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vistagen (VTGN) hires Angel S. Angelov, MD, MBA as Chief Medical Officer with option grant - Stock Titan
VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen appoints Angel S. Angelov as chief medical officer - marketscreener.com
Vistagen appoints Angel Angelov as chief medical officer By Investing.com - Investing.com Australia
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - Yahoo Finance
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Insider Monkey
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
[SCHEDULE 13G/A] Vistagen Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
All News about Vistagen Therapeutics, Inc.Common Stock - The Chronicle-Journal
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - marketscreener.com
Vistagen Therapeutics, Inc.Common Stock (NQ: VTGN - FinancialContent
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Vistagen Reports Positive 12-Month Data for Fasedienol Nasal Spray in Social Anxiety Disorder Phase 3 Trial - Minichart
Vistagen (VTGN) Reports Positive Data from Fasedienol Study for Social Anxiety - GuruFocus
VistaGen Reports Positive Long-Term Data for Fasedienol - TipRanks
Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety disorder - marketscreener.com
Vistagen announces positive OLE safety and 4-month efficacy signals for fasedienol in social anxiety - TradingView
Vistagen (NASDAQ: VTGN) reports positive PALISADE-3 OLE results - Stock Titan
Vistagen reports preliminary data from social anxiety trial By Investing.com - Investing.com Canada
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - marketscreener.com
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-05-10 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Trial of Fasedienol Nasal Spray for Social Anxiety Disorder; Topline Results Expected Q2 2026 - Minichart
ex_558852.htm - SEC.gov
Vistagen (VTGN) completes PALISADE-4 randomized phase, eyes Q2 2026 data - Stock Titan
Vistagen (VTGN) Wraps Up Final Patient Visits in Phase 3 Anxiety Trial - GuruFocus
Vistagen completes enrollment in phase 3 anxiety trial By Investing.com - Investing.com Canada
Public-speaking challenge study ends; Vistagen data due this quarter - Stock Titan
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Yahoo Finance
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect | NDAQ:VTGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) S - The National Law Review
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Vistagen (VTGN) wins FDA go-ahead to advance refisolone Phase 2 hot flash studies - Stock Titan
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe
VistaGen appoints Nick Tressler as CFO - MSN
VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Vistagen Therapeutics Inc (VTGN) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):